Helena VonVille

Ms. Helena VonVille

Health Sciences Library System, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SAShailesh M. Advani
Shailesh M. Advani
PAPragati G. Advani
Pragati G. Advani
HVHelena VonVille
Helena VonVille
SJSyed Hasan Raza Jafri
Syed Hasan Raza Jafri
Cachexia is a multisystem syndrome characterized by weight loss, anorexia, loss of muscle mass, systemic inflammation, insulin resistance, and functional decline. Management of cachexia involves addressing multiple underlying biological mechanisms. Previous review on pharmacological management of cancer cachexia identified progestins and corticosteroids as effective agents for treatment of cachexia. However, to date no consensus exists on a single effective or standard treatment for management of cachexia. The aim of this systematic review is to determine the effectiveness of pharmacological treatments used to manage cachexia among adult cancer patients. We performed literature searches of PubMed (NLM), Embase (Ovid), and Medline(Ovid) to identify clinical trials focused on pharmacological management of cancer cachexia among adult cancer patients from 2004 to 2018. Three reviewers screened a random selection of abstracts to measure for interrater reliability. After this step, each screener screened two-thirds of all abstracts and 177 studies were identified for full text review. The primary outcome was impact of pharmacological management on change in either weight or lean body mass in cancer patients. We identified 19 articles (representing 20 RCTs) that focused on pharmacological management of cancer cachexia. Agents showing promising results included Anamorelin and Enobosarm. Anamorelin at 50 or 100 mg per day for 12 weeks showed a consistent benefit across all studies and resulted in significant improvement in weight as compared to baseline among cancer patients. Enobosarm at 1 and 3 mg per day was also effective in improving lean body mass and QOL symptoms among advancer stage cancer patients. Finally, use of combination agents provide evidence for targeting multiple pathways underlying cachexia mechanism to achieve maximum benefit. No agents showed functional improvement in cancer patients. Anamorelin as a single agent shows promising results in improving cachexia related weight loss among cancer patients. Further research on combination therapies may be helpful to address critical gaps in cachexia management.

18 May 2021 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
JDJennie Dorris
Jennie Dorris
SNStephen Neely
Stephen Neely
LTLauren Terhorst
Lauren Terhorst
HVHelena VonVille
Helena VonVille
JRJuleen Rodakowski
Juleen Rodakowski
Objectives: To examine randomized controlled trials with active music‐making interventions, in which older adults with probable mild cognitive impairment (MCI) or dementia physically participate in music, and their effects on cognitive functioning, emotional well‐being, and social engagement. Participating in music‐making is engaging and has shown diverse benefits. Additionally, this review categorized the music activities of each intervention. Design: Systematic review and meta‐analysis. Setting: Long‐term care facilities, day centers, specialty outpatient units, and community. Methods: Published randomized controlled trials of active music‐making interventions to support older adults with probable MCI or dementia were identified (to March 15, 2021) using searches on Medline (Ovid), APA PsycInfo (Ovid), CINAHL (Ebsco), and Embase (Elsevier). The outcomes were cognitive functioning, emotional well‐being, and social engagement, including self‐ and clinician‐reported measures such as the Mini‐Mental State Examination, Positive and Negative Affect Schedule, and the Beck Depression Inventory. Studies were critically appraised and studies with similar methodology were meta‐analyzed. Participants: Older adults with probable MCI and mild or moderate dementia. Results: A total of 21 studies with 1472 participants were analyzed for potential effect sizes and intervention activities. Of the 21 studies, nine studies recruiting a total of 495 participants were used to produce a random‐effects meta‐analytic model for cognitive functioning. Music showed a small, positive effect on cognitive functioning; the combined standard mean difference for the experimental and control group was 0.30 (95% confidence interval [CI] 0.10, 0.51). There was low study heterogeneity, with an I 2 of 24% ( p = 0.004). Individual studies for emotional well‐being in terms of quality of life and mood showed positive effect sizes, d = 1.08 and d = 1.74, respectively. [Corrections added on July 8, 2021, after first online publication: The preceding sentences were revised from: “… control group was 0.31 (95% confidence interval [CI] 0.10,0.52). There was low study heterogeneity, with an I2 of 25% ( p = 0.004).”] Conclusion: This review shows that music‐making has a small but statistically significant effect on cognitive functioning for older adults with probable MCI or dementia. Future music interventions can benefit from rigorous intervention protocols that isolate specific activities.

1 October 2018 in Translational Oncology
Verified
Journal Article
Open access
SAShailesh Advani
Shailesh Advani
PAPragati Advani
Pragati Advani
SDStacia M. DeSantis
Stacia M. DeSantis
DBDerek Brown
Derek Brown
HVHelena VonVille
Helena VonVille
SKScott Kopetz
Scott Kopetz
CpG island methylator phenotype (CIMP) tumors, comprising 20% of colorectal cancers, are associated with female sex, age, right-sided location, and BRAF mutations. However, other factors potentially associated with CIMP have not been robustly examined. This meta-analysis provides a comprehensive assessment of the clinical, pathologic, and molecular characteristics that define CIMP tumors. We conducted a comprehensive search of the literature from January 1999 through April 2018 and identified 122 articles, on which comprehensive data abstraction was performed on the clinical, pathologic, molecular, and mutational characteristics of CIMP subgroups, classified based on the extent of DNA methylation of tumor suppressor genes assessed using a variety of laboratory methods. Associations of CIMP with outcome parameters were estimated using pooled odds ratio or standardized mean differences using random-effects model. We confirmed prior associations including female sex, older age, right-sided tumor location, poor differentiation, and microsatellite instability. In addition to the recognized association with BRAF mutations, CIMP was also associated with PIK3CA mutations and lack of mutations in KRAS and TP53. Evidence of an activated immune response was seen with high rates of tumor-infiltrating lymphocytes (but not peritumoral lymphocytes), Crohn-like infiltrates, and infiltration with Fusobacterium nucleatum bacteria. Additionally, CIMP tumors were associated with advance T-stage and presence of perineural and lymphovascular invasion. The meta-analysis highlights key features distinguishing CIMP in colorectal cancer, including molecular characteristics of an active immune response. Improved understanding of this unique molecular subtype of colorectal cancer may provide insights into prevention and treatment.

1 May 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
LPLauren S. Prescott
Lauren S. Prescott
JTJolyn S. Taylor
Jolyn S. Taylor
MLMaria A. Lopez-Olivo
Maria A. Lopez-Olivo
MMMark F. Munsell
Mark F. Munsell
HVHelena VonVille
Helena VonVille
DBDiane C Bodurka
Diane C Bodurka

1 January 2013 in Pediatrics
Verified
Journal Article
Closed access
PDF file
HRHeidi V. Russell
Heidi V. Russell
JPJanki Panchal
Janki Panchal
HVHelena VonVille
Helena VonVille
LFLuisa Franzini
Luisa Franzini
JSJ. Michael Swint
J. Michael Swint
OBJECTIVE: Although there is a growing national focus on health care cost containment and accountability in resource utilization, childhood cancer therapy costs continue to increase without proportionate survival improvements. Economic evaluations (EEs) such as cost and/or cost effectiveness analysis may identify areas to improve resource efficiency. This review aims to identify and characterize the EE studies performed in this field. METHODS: We performed a structured literature search of the Medline, PubMed, and the National Health Service EE databases from 2000 to 2011. Concepts for the search included “cost analyses,” “child,” and “cancer.” Studies were limited to original research, comparison of 2 or more treatments using monetary units, English language, and originating from economically developed countries. Identified studies were assessed by the Drummond checklist and characterized by the therapy studied, data sources, and research perspectives. RESULTS: Forty studies met inclusion criteria. Eleven studied chemotherapy, surgery, or radiation. Twenty-nine studied supportive measures such as growth factor support or treatment of infection. The median Drummond score was 6 of 10 (range, 2–9). Only 15 (36%) included treatment outcomes when comparing costs. Methodological limitations were common. CONCLUSIONS: A wide variety of topics and methodological limitations made comparisons between studies difficult. Strategies for increasing the generalizability of future EE studies are presented. Substantial opportunity exists for EE research in childhood cancer.